澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

DIMERIX LTD

0.250

0.000

成交量：81.08萬

成交額：20.16萬

市值：1.50億

市盈率：-5.03

高：0.255

開：0.250

低：0.245

收：0.250

52周最高：0.665

52周最低：0.157

股本：6.00億

流通股本：4.68億

量比：0.56

換手率：0.17%

股息：- -

股息率：- -

每股收益(TTM):-0.050

每股收益(LYR):-0.050

淨資產收益率：-594.54%

總資產收益率：-29.36%

市淨率：-10.17

市盈率(LYR):-5.03

資料載入中...

總覽公司新聞公告

公司資料

公司名字：

DIMERIX LTD

交易所：

ASX

成立時間：

- -

員工人數：

15

公司地址：

425 Smith Street,Fitzroy,Victoria,Australia

官網：

http://dimerix.com

郵編：

3065

電話：

傳真：

61 8 9388 8256

簡介：

Dimerix Limited, a clinical stage biotechnology company, develops and commercializes new therapies in the area of unmet medical needs. Its lead product candidate is DMX-200, which is in Phase II clinical trial for the treatment of diabetic kidney diseases and focal segmental glomerulosclerosis. The company is headquartered in Fitzroy, Australia.

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/DXB.AU/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"DXB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"DXB.AU\",,,,,undefined,":{"symbol":"DXB.AU","market":"AU","secType":"STK","nameCN":"DIMERIX LTD","latestPrice":0.25,"timestamp":1789107120000,"preClose":0.25,"halted":0,"volume":810805,"delay":0,"changeRate":0,"nameEN":"DIMERIX LTD","floatShares":467696880,"shares":600396776,"eps":-0.0497,"marketStatus":"休市中","change":0,"latestTime":"09-11 16:12:00 AEST","open":0.25,"high":0.255,"low":0.245,"amount":201578,"amplitude":0.04,"askPrice":0.25,"askSize":115024,"bidPrice":0.245,"bidSize":25000,"shortable":3,"etf":0,"ttmEps":-0.0497,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1789344000000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.25,"openAndCloseTimeList":[[1789084800000,1789106400000]],"volumeRatio":0.5605546718641254,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"DXB.AU","preClose":0.25,"auctionPrice":0.25,"auctionVolume":7021,"auction":3,"marketStatus":"盘后竞价","timestamp":1789106991055}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"DXB.AU\",,,,,undefined,":{"symbol":"DXB.AU","floatShares":467696880,"roa":"-29.36%","roe":"-594.54%","lyrEps":-0.0497,"volumeRatio":0.5605546718641254,"shares":600396776,"dividePrice":0,"high":0.255,"amplitude":0.04,"preClose":0.25,"low":0.245,"week52Low":0.157,"pbRate":"-10.17","psRate":"23.62","week52High":0.665,"institutionHeld":0,"latestPrice":0.25,"committee":-0.642918,"eps":-0.0497,"divideRate":0,"volume":810805,"delay":0,"ttmEps":-0.0497,"open":0.25,"prevYearClose":0.55,"prevWeekClose":0.285,"prevMonthClose":0.28,"prevQuarterClose":0.205,"fiveDayClose":0.285,"twentyDayClose":0.295,"sixtyDayClose":0.225,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DXB.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DXB.AU\",market:\"AU\",,,undefined,":[],"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":23928564,"employeeNum":15,"address":"425 Smith Street,Fitzroy,Victoria,Australia","zipCode":"3065","officePhone":"1300 813 321","officeFax":"61 8 9388 8256","fiscalYearEnd":"06-30"},"stockCompanyDetail":{"websiteUrl":"http://dimerix.com","stockEarnings":[{"period":"1week","weight":-0.1228},{"period":"1month","weight":-0.1379},{"period":"3month","weight":0.5152},{"period":"6month","weight":-0.2857},{"period":"1year","weight":-0.4681},{"period":"ytd","weight":-0.5455}],"compareEarnings":[{"period":"1week","weight":-0.0144},{"period":"1month","weight":-0.026},{"period":"3month","weight":0.0239},{"period":"6month","weight":0.0491},{"period":"1year","weight":0.0897},{"period":"ytd","weight":0.0274}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"description":"Dimerix Limited, a clinical stage biotechnology company, develops and commercializes new therapies in the area of unmet medical needs. Its lead product candidate is DMX-200, which is in Phase II clinical trial for the treatment of diabetic kidney diseases and focal segmental glomerulosclerosis. The company is headquartered in Fitzroy, Australia.","yearOnYearQuotes":[{"month":1,"riseRate":0.181818,"avgChangeRate":-0.092931},{"month":2,"riseRate":0.454545,"avgChangeRate":0.020467},{"month":3,"riseRate":0.363636,"avgChangeRate":0.019402},{"month":4,"riseRate":0.272727,"avgChangeRate":0.014529},{"month":5,"riseRate":0.545455,"avgChangeRate":0.055282},{"month":6,"riseRate":0.818182,"avgChangeRate":0.166318},{"month":7,"riseRate":0.333333,"avgChangeRate":0.071825},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.067379},{"month":9,"riseRate":0.363636,"avgChangeRate":0.171129},{"month":10,"riseRate":0.181818,"avgChangeRate":-0.090222},{"month":11,"riseRate":0.272727,"avgChangeRate":0.028595},{"month":12,"riseRate":0.454545,"avgChangeRate":0.04297}],"exchange":"ASX","name":"DIMERIX LTD","nameEN":"DIMERIX LTD"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"DXB.AU\",market:\"AU\",,,undefined,":null}}